

# Nabeel Khan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4966188/publications.pdf>

Version: 2024-02-01

51  
papers

1,400  
citations

331538

21  
h-index

345118

36  
g-index

51  
all docs

51  
docs citations

51  
times ranked

1915  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Vedolizumab in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 734-744.	0.9	15
2	Efficacy of Recombinant Zoster Vaccine in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1570-1578.e1.	2.4	13
3	The impact of IBD medications on risk of pneumonia and pneumonia-related hospitalisation: a nationwide cohort study of 56 410 IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 64-72.	1.9	10
4	Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1505-1507.	0.6	4
5	Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis. <i>BMC Gastroenterology</i> , 2022, 22, 177.	0.8	4
6	Prevalence of SARS-COV-2 Vaccination and Factors Impacting Likelihood of Vaccination in a Nationwide Veterans Affairs Cohort of IBD Patients. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1776-1780.	0.9	1
7	Letter: screening for infectious side effects in patients with IBD—the importance and potential of real-world remote monitoring. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 262-262.	1.9	0
8	Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affairs Healthcare System. <i>Gut</i> , 2021, 70, 1657-1664.	6.1	42
9	Incidence of Infections and Malignancy Among Elderly Male Patients with IBD Exposed to Vedolizumab, Prednisone, and 5-ASA Medications: A Nationwide Retrospective Cohort Study. <i>Advances in Therapy</i> , 2021, 38, 2586-2598.	1.3	13
10	The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients. <i>Crohn's &amp; Colitis</i> 360, 2021, 3, .	0.5	6
11	Reply. <i>Gastroenterology</i> , 2021, 160, 1904.	0.6	0
12	Risk of Venous Thromboembolism Among Patients With Inflammatory Bowel Disease Who Contract Severe Acute Respiratory Syndrome Coronavirus 2. <i>Gastroenterology</i> , 2021, 161, 1709-1711.e1.	0.6	5
13	Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications. <i>Gastroenterology</i> , 2021, 161, 827-836.	0.6	83
14	Are Patients With Inflammatory Bowel Disease at an Increased Risk of Developing SARS-CoV-2 than Patients Without Inflammatory Bowel Disease? Results From a Nationwide Veterans' Affairs Cohort Study. <i>American Journal of Gastroenterology</i> , 2021, 116, 808-810.	0.2	25
15	Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk. <i>American Journal of Gastroenterology</i> , 2021, 116, 741-747.	0.2	16
16	Repeated Occurrences of Basal Cell Cancer in Patients With Inflammatory Bowel Disease Treated With Immunosuppressive Medications. <i>American Journal of Gastroenterology</i> , 2020, 115, 1246-1252.	0.2	11
17	Impact of Anti-Tumor Necrosis Factor and Thiopurine Medications on the Development of COVID-19 in Patients With Inflammatory Bowel Disease: A Nationwide Veterans Administration Cohort Study. <i>Gastroenterology</i> , 2020, 159, 1545-1546.e1.	0.6	56
18	Adherence of Infusible Biologics During the Time of COVID-19 Among Patients With Inflammatory Bowel Disease: A Nationwide Veterans Affairs Cohort Study. <i>Gastroenterology</i> , 2020, 159, 1592-1594.e1.	0.6	17

#	ARTICLE	IF	CITATIONS
19	Incidence, Duration, and Management of Anemia: A Nationwide Comparison Between IBD and Non-IBD Populations. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 934-940.	0.9	6
20	Factors Predicting Severity of Herpes and Improving Herpes Vaccination Among IBD Patients. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e24-e24.	0.9	0
21	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2824.	2.4	0
22	Mortality Associated With Development of Squamous Cell Cancer in Patients With Inflammatory Bowel Diseases Receiving Treatment With Thiopurines. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2262-2268.	2.4	7
23	Risk of Infection and Types of Infection Among Elderly Patients With Inflammatory Bowel Disease: A Retrospective Database Analysis. <i>Inflammatory Bowel Diseases</i> , 2019, 26, 462-468.	0.9	27
24	Efficacy of Live Attenuated Herpes Zoster Vaccine in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1341-1347.	2.4	23
25	Frequency of Herpes Zoster Vaccination Among Inflammatory Bowel Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 345-351.	0.9	18
26	Frequency of Surveillance and Impact of Surveillance Colonoscopies in Patients With Ulcerative Colitis Who Developed Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e289-e292.	1.0	7
27	Management of Anemia in Patients with Inflammatory Bowel Disease (IBD). <i>Current Treatment Options in Gastroenterology</i> , 2018, 16, 112-128.	0.3	33
28	Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1919-1927.e3.	2.4	104
29	Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti-TNF medications" authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 448-448.	1.9	0
30	Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age. <i>Advances in Therapy</i> , 2017, 34, 542-559.	1.3	72
31	Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature. <i>Current Treatment Options in Gastroenterology</i> , 2017, 15, 116-125.	0.3	30
32	Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists. <i>British Journal of Dermatology</i> , 2017, 177, 1086-1092.	1.4	22
33	Segmental resection is a safe oncological alternative to total proctocolectomy in elderly patients with ulcerative colitis and malignancy. <i>Colorectal Disease</i> , 2017, 19, 1108-1116.	0.7	21
34	A Novel User-Friendly Model to Predict Corticosteroid Utilization in Newly Diagnosed Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 991-997.	0.9	10
35	A Novel Model for Predicting Incident Moderate to Severe Anemia and Iron Deficiency in Patients with Newly Diagnosed Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1295-1304.	1.1	4
36	The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index ( CDASI ) among dermatologists, rheumatologists and neurologists. <i>British Journal of Dermatology</i> , 2017, 176, 423-430.	1.4	19

#	ARTICLE	IF	CITATIONS
37	Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 668-672.	1.9	24
38	Elderly-Onset and Adult-Onset Ulcerative Colitis Are More Similar than Previously Reported in a Nationwide Cohort. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2857-2862.	1.1	4
39	Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients. <i>Drugs and Aging</i> , 2017, 34, 859-868.	1.3	35
40	Albumin as a prognostic marker for ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 8008-8016.	1.4	50
41	Factors Predicting Testing and Treatment of Iron Deficiency in a Nationwide Cohort of Anemic UC Patients. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2894-2901.	0.9	8
42	Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort. <i>PLoS ONE</i> , 2016, 11, e0158017.	1.1	111
43	Optimal management of steroid-dependent ulcerative colitis. <i>Clinical and Experimental Gastroenterology</i> , 2015, 8, 293.	1.0	18
44	Risk of Melanoma and Non-Melanoma Skin Cancer in Ulcerative Colitis Patients Treated With Thiopurines: A Nationwide Retrospective Cohort. <i>American Journal of Gastroenterology</i> , 2014, 109, 1781-1793.	0.2	73
45	Letter: predictors of severe disease in ulcerative colitis - the same or different in Crohn's disease? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1121-1122.	1.9	0
46	Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1699-1708.	1.0	30
47	Risk of Lymphoma in Patients With Ulcerative Colitis Treated With Thiopurines: A Nationwide Retrospective Cohort Study. <i>Gastroenterology</i> , 2013, 145, 1007-1015.e3.	0.6	201
48	Prevalence and Predictors of Low Bone Mineral Density in Males With Ulcerative Colitis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2368-2375.	1.8	22
49	Methotrexate in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1379-1383.	0.9	23
50	Long-Term Mesalamine Maintenance in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1123-1129.	0.9	32
51	Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 755-764.	1.9	45